Home » Topics » BioWorld Science

BioWorld Science
RSS

RemeGen receives Australian ethics approval for phase I trial of ADC RC-118

Aug. 2, 2021

Changes in SavaDx and plasma P-tau181 confirm treatment effect of simufilam in AD

Aug. 2, 2021

Addition of GEN-1 to standard NAC shows safety and efficacy in phase I ovarian cancer study

Aug. 2, 2021

Deuterated GC-376 variants show efficacy in model of SARS-CoV-2 infection

Aug. 2, 2021

Jiangsu Simcere Pharmaceutical R&D discovers MAT2A inhibitors

Aug. 2, 2021

Beijing Kang Dini Pharmaceutical presents new IL-8 expression inhibitors

Aug. 2, 2021

Enyo reports promising phase II data for vonafexor in patients with chronic hepatitis B

Aug. 2, 2021

DNA-dependent protein kinase inhibitors discovered at Chengdu Baiyu Pharmaceutical

Aug. 2, 2021

New glucocorticoid receptor modulators identified at Medshine Discovery

Aug. 2, 2021

FDA clears IND for phase I study of Protollin as treatment of AD

Aug. 2, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...